Takeda: Growth and Emerging Markets Unit Aims at Double-Digit Revenue Growth In 10 Yrs

 

• Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030
• Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets
• Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targeted portfolio investments in the Company’s highly innovative 14 Global Brands and Wave 1 pipeline assets.

“Building upon Takeda’s global vision to bring long-term value to patients, society and shareholders, we have sharpened our regional strategy to deliver healthcare in geographies that include 85% of the world’s population. As a purpose-led, patient-centric and values-based company, our portfolio combines innovative therapies with the right degree of scale to be competitive. Together with attractive market fundamentals and an executive team equipped to deliver strong business performance, we are committed to delivering sustainable revenue growth while increasing patient access to our life-saving and life-transforming treatments,” said Ricardo Marek, President of Growth & Emerging Markets Business Unit at Takeda.

With 95%3 of GEM BU’s current revenues coming from innovative treatments aligned with the company’s five key business areas, GEM BU has an ambition to outpace forecasted market revenue growth for the region over the next ten years. As a vast geographic area with a combined population of 6.5 billion, the Emerging Markets region presents significant growth opportunities in unmet patient needs across key therapy areas, which we believe can be achieved by a globally-aligned ‘access-first’ strategy.

“Emerging Markets will be a key source of revenue and momentum for Takeda over the next decade, with a strategy aligned to our global innovation focus,” said Costa Saroukos, Takeda chief financial officer. “Through targeted investments in the portfolio and key markets, we expect growth of the GEM BU to outpace the market for specialized, innovative treatments, as we expand our 14 global brands and launch our Wave 1 pipeline assets in the region.”

https://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Growth+and+Emerging+Markets+Business+Unit+Aims+to+Deliver+Double-Digit+Revenue+Growth+Over+Next+Decade%C2%B9/18113241.html